Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07471217) titled '[¹4C] Hydronidone Mass Balance Study' on March 10.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Beijing Continent Pharmaceutical Co, Ltd.

Condition: Chronic Hepatitis B-related Liver Fibrosis

Intervention: Drug: [¹4C]Hydronidone

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: April 30, 2026

Target Sample Size: 8

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07471217

Published by HT Digital Co...